
The use of 90Y-FAPI-46 radioligand therapy resulted in controlled disease progression in nearly half of a 30-person cohort largely comprised of patients with advanced sarcomas, according to new research presented at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting.





























